Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News German watchdog criticises EMA adaptive pathways approval Cost effectiveness agency critical of real world evidence plans
Views & Analysis The EMA’s Adaptive Pathways: are safety concerns exaggerated... Companies still need to provide a compelling case for efficacy
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
